Psychedelics for Alcoholism

Q&A with Clearmind Management

March 30, 2022

Clearmind’s Management Answers Questions Related to the Potential Treatment for Alcohol Use Disorder and Binge Drinking Based on Its Psychoactive Molecule MEAI


Adi Zuloff-Shani, PhD

Clearmind's Chief Executive Officer

Dr. Adi Zuloff-Shani is a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

Clearmind's VP of Business Development

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia's School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.


Shannon Smadella

Wellness Personality & Podcast Host, Executive Consultant, Former Miss Canada

Shannon has interviewed some of the most prominent leaders, scientists, doctors and thinkers in the psychedelic space. She was the host/co-organizer of Seasons 1 & 2 of "Examining The Psychedelic Renaissance" with MAPS Canada and the Inaugural World Psychedelics Day [6.20] She has worked in business for the past 20 years, raising millions for various charities & organizations, including those in psychedelics.